Inside Immatics

Inside Immatics / About

About
Immatics

Immatics combines the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors with the goal of enabling a robust and specific T cell response against these targets.

This deep know-how is the foundation for our pipeline of Adoptive Cell Therapies and TCR Bispecifics as well as our partnerships with global leaders in the pharmaceutical industry. We are committed to delivering the power of T cells and to unlocking new avenues for patients in their fight against cancer.

Learn more about
how we aim to deliver the power of T cells to cancer patients in our corporate video

You are currently viewing a placeholder content from YouTube. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.

More Information
Unblock content Accept required service and unblock content

Quick Facts

>400

TEAM
MEMBERS

in Tübingen and Munich, Germany and Houston, Texas

3

GLOBAL
SITES

4

CLINICAL
PROGRAMS

2

THERAPEUTIC
MODALITIES

TCR-T and TCR Bispecifics in clinical development

2

TECHNOLOGY
PLATFORMS

for target and TCR discovery

200+

TARGETS

across major solid tumors

Immatics
at a Glance

Unlocking new T cell receptor-based immunotherapies by identifying true targets:
Immatics brings together a breadth of technologies matched with deep knowledge of cancer-specific targets and TCRs to achieve the next advance in immunotherapy.

We have
inner
insight

Immatics has identified and characterized a trove of novel intracellular tumor targets for the development of cancer immunotherapies. We use this knowledge together with our XPRESIDENT® technology to define true targets, distinct molecular barcodes that identify the tumor cell. This gives us a drug discovery advantage that we aim to leverage for our own proprietary pipeline and for our collaborations with world-leading partners.

We pioneer novel
therapeutic
approaches

TCRs represent a new therapeutic opportunity for engaging T cells against cancer and for attacking the tumor microenvironment. These new treatments are designed to cross cancer’s protective barriers and make a therapeutic impact. Immatics continues to innovate using the right TCRs to develop both Adoptive Cell Therapies and novel antibody-like TCR Bispecifics.

We refine and
engineer our
drug candidates

Through our XCEPTOR®-based process of testing the specificity, affinity and functionality of our TCRs to engage with cancer cells, our drug candidates use the full power of T cells to fight tumor cells.

Our purpose is
to make a difference
for patients

We have a big goal: overcoming the challenges of fighting cancer and bringing new therapeutic opportunities to cancer patients with high medical need. We will do this with passion and relentless focus to achieve better outcomes for patients.

From Target
to Bedside

Immatics’ approach towards the goal of opening new avenues of treatment for cancer patients starts with the discovery and validation of true targets (using the XPRESIDENT® platform). In the next step, Immatics identifies, engineers and validates delivering the power of T cells to cancer patients.

Company
History

Since its foundation in 2000 as a spin out from H.G. Rammensee’s laboratory at University of Tübingen, Germany, Immatics has revolutionized the identification of tumor-associated pHLA targets, which are recognized by T cells. Identifying true cancer targets that are presented on tumor tissue but not on healthy cells and the subsequent discovery, selection, and engineering of a therapeutic TCR are central to Immatics‘ mission: Delivering the power of T cells to cancer patients and advance the next wave in cancer immunotherapy.

In 2015, Immatics and MD Anderson Cancer Center launched Immatics US, Inc. in Houston, Texas as a joint venture to develop transformative Adoptive Cell Therapies.